PURPOSE: To investigate choroidal topographic changes by swept-source optical coherence tomography (Swept-OCT) in @entity1 undergoing intravitreal injections of @entity7 ( @entity7 ) for exudative @entity1020 ( @entity1020 ). DESIGN: Prospective interventional study. METHODS: Consecutive @entity1 with unilateral treatment-na  ve exudative @entity1020 were entered into the study  over 6  months. Changes in choroidal thickness after intravitreal ranibizumab injections, overall in the macula and in neovascular and non-neovascular areas, from baseline to month 3 (loading phase) and month 6 (pro re nata phase), were investigated by means of Swept-OCT maps. RESULTS: Forty-one eyes of 41 @entity1 (mean age: 79.4    7.3 years) were analyzed. @entity3193 at study entry was significantly thicker in the study eyes as compared to fellow eyes (P < .05). Analysis of sectorial choroidal thickness over time in study eyes revealed a significant @entity2295 and non-neovascular areas from baseline to month 3 and month 6 (P < .0001 for all). Central choroidal thickness revealed significant variation between treated and fellow eyes from baseline to month 3 (P  = .017) and month 6 (P  = .045). The @entity227 was significantly higher (P  = .02) in @entity1 with a larger @entity3193 (>= 29   m, n  = 11) vs the others (n  = 30). CONCLUSIONS: The thinning of the macular choroid (affected or not by @entity1940 ), along with the significantly thicker choroid in exudative @entity1020 before treatment initiation compared to fellow eyes, allows the hypothesis that anti- @entity7 treatment may favorably influence the choroidal exudation by reducing @entity455 .

Assessment of Choroidal Topographic Changes by Swept-Source Optical Coherence Tomography After Intravitreal Ranibizumab for Exudative Age-Related XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual gain'] @entity455 :: ('MESH:D014652', 'Disease') :: ['choroidal vascular hyperpermeability'] @entity1940 :: ('MESH:D020256', 'Disease') :: ['choroidal neovascularization'] @entity7 :: ('7422', 'Gene') :: ['VEGF', 'anti-vascular endothelial growth factor'] @entity2295 :: ('MESH:D015861', 'Disease') :: ['reduction in both neovascular'] @entity3193 :: ('MESH:D015862', 'Disease') :: ['Choroidal thickness', 'choroidal thickness reduction'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['AMD eyes', 'AMD', 'age-related macular degeneration']
@entity1020 :: (MESH:D008268,Disease) :: ['Macular Degeneration']
